Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Key Points
Epidermal growth factor receptor (
EGFR
)-mutant tumours define a unique subset of non-small-cell lung cancer (NSCLC). These tumours display sensitivity to small-molecule EGFR tyrosine kinase inhibitors (TKIs).
Prospective clinical trials have now validated the correlation between EGFR mutation and TKI sensitivity.
Multipl...
Alternative Titles
Full title
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3072803
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3072803
Other Identifiers
ISSN
1474-175X
E-ISSN
1474-1768
DOI
10.1038/nrc2947
